Latest News and Press Releases

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on...

HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance...

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UN QUATRIÈME CAS CONSÉCUTIF DE RÉPONSE AVEC LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN...

PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA...

FOR IMMEDIATE RELEASE -- ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 -- Updated clinical data presented at ASH show robust efficacy,...

ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting Marseille, France, December 5, 2025 05:00 a.m. ET / 11:00 a.m. CET– ImCheck Therapeutics announced...

New York, USA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight Acute...

Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML